Delving into the Latest Updates on FAB Pharma SAS with Synapse

Overview

Basic Info

Introduction

FAB Pharma SAS is a biopharmaceutical company that specializes in developing drugs to treat bacterial infections. In addition to drug development, the company offers pharmaceutical research services. FAB Pharma SAS is dedicated to creating therapeutics that address current antibiotics resistance issues and help control severe bacterial infections. The company's products are low-molecular-weight antibacterial molecules designed for enzymes in Fatty Acid Biosynthesis I. Founded by Stefan Fischer on June 15, 2009, FAB Pharma SAS is headquartered in Paris, France.

ABSTRACT MUT056399 is a highly potent new inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli. In vitro , MUT056399 was very active against S. aureus strains, including methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), linezolid-resistant, and multidrug-resistant strains, with MIC 90 s between 0.03 and 0.12 μg/ml. MUT056399 was also active against coagulase-negative staphylococci, with MIC 90 s between 0.12 and 4 μg/ml. The antibacterial spectrum is consistent with specific FabI inhibition with no activity against bacteria using FabK but activity against FabI-containing Gram-negative bacilli. In vitro , resistant clones of S. aureus were obtained at a low frequency. All of the resistant clones analyzed were found to contain mutations in the fabI gene. In vivo , MUT056399, administered subcutaneously, protected mice from a lethal systemic infection induced by MSSA, MRSA, and vancomycin-intermediate S. aureus strains (50% effective doses ranging from 19.3 mg/kg/day to 49.6 mg/kg/day). In the nonneutropenic murine thigh infection model, the same treatment with MUT056399 reduced the bacterial multiplication of MSSA and MRSA in the thighs of immunocompetent mice. These properties support MUT056399 as a very promising candidate for a novel drug to treat severe staphylococcal infections.

100 Deals associated with FAB Pharma SAS

Login to view more data

100 Translational Medicine associated with FAB Pharma SAS

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Oct 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data